Press Releases
Fellow is a high-complexity mail-in semen analysis lab and the largest dedicated semen analysis facility in the U.S., with over 200,000 samples analyzed to date. Our clinically validated mail-in process¹ accounts for semen degradation over time—making it the only mail-in test proven to match the accuracy of a traditional 1-hour analysis.
Fellow Health announced today the close of a $24 million Series B financing round led by 5AM Ventures, with new participation from The Forest Road Company.
Fellow Semen Analysis is now a covered benefit for eligible Progyny members to support the growing need for semen analysis as a critical step in the fertility care journey.
Fellow received a high-complexity laboratory permit from the NYS Department of Health Clinical Laboratory Evaluation Program, and approval for its post-vasectomy test.
Fellow presented studies highlighting mail-in semen analysis as a potential post-PSA reflex test as well as an alternative to in-clinic post-vasectomy semen analysis (PVSA).
Fellow announced research showing that seminal plasma is a rich source of cell free DNA from somatic cells and provides new insights into its potential as a liquid biopsy.
Fellow announced reserach findings demonstrating that its mail-in postvasectomy semen analysis (PVSA) kits significantly improve compliance rates.
Fellow achieved a significant milestone of delivering more than 100,000 patient test results since its product launch in 2020.
For media inquiries, email media@meetfellow.com.
Learn more about…
Samplaski et al. Development and validation of a novel mail-in semen analysis system and the correlation between one hour and delayed semen analysis testing; Fertil Steril. 2021;115(4):922-929
